Companion Diagnostics Under the IVDR: Aligning the Test and the Medicine

Targeted therapies increasingly depend on a test that decides which patients should receive them. Under the In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746, that test, the companion diagnostic, has its own conformity assessment, and the medicines regulator must be consulted on it. Medicine and diagnostic timelines that are not aligned can delay launch even when the medicine itself is ready.

What counts as a companion diagnostic

The IVDR defines a companion diagnostic (CDx) as a device essential for the safe and effective use of a corresponding medicinal product. It identifies patients most likely to benefit, or patients at increased risk of serious adverse reactions, before or during treatment. Under the Annex VIII classification rules, companion diagnostics are at least class C. They therefore need a notified body, and self-certification is not an option.

The consultation with the medicines regulator

Before issuing a certificate, the notified body must obtain a scientific opinion on whether the device is suitable for use with the medicinal product concerned:

  • EMA is consulted where the medicine falls within the mandatory scope of the centralised procedure, and should also be consulted for other centrally authorised products.
  • A national competent authority is consulted for medicines authorised nationally.
  • Under EMA’s procedural guidance, the opinion is due within 60 days, which can be extended once by up to a further 60 days on justified grounds.
  • The notified body should announce the submission at least three months in advance.
  • Later changes affecting the device’s performance or intended use can trigger a follow-up consultation, with a 30-day opinion timeline.

The opinion focuses on suitability: scientific validity, analytical performance and clinical performance as they relate to the medicine. The consultation package includes draft instructions for use and the summary of safety and performance.

Synchronising two procedures

The marketing authorisation application and the CDx conformity assessment run on separate tracks with different assessors. Practical alignment points include:

  • consistent biomarker definitions, cut-offs and intended-use wording across the SmPC and the IFU
  • using the same assay, or a bridged version of it, in the pivotal clinical trial
  • booking notified body capacity early, because CDx expertise remains scarce
  • planning label updates when a new indication requires a new or extended CDx claim.

The access dimension

A CE-marked test does not guarantee patients can get it. If biomarker testing is not reimbursed or not available in the hospital laboratories that treat the patients, uptake of the medicine will suffer. In Greece, testing pathways, laboratory capacity and funding should be part of the access plan from the start, not left until after launch.

How PQRA helps

PQRA works across medicines and medical device regulation. We help sponsors and diagnostic partners plan CDx strategy, align SmPC and IFU claims, prepare for consultation with the notified body and the regulator, and build the testing pathway into the Greek market access plan.

Plan your companion diagnostic strategy with PQRA →

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *